Breaking News Instant updates and real-time market news.

AIMT

Aimmune

$21.74

-0.15 (-0.69%)

, DBVT

DBV Technologies

$14.12

-0.58 (-3.95%)

17:22
12/19/18
12/19
17:22
12/19/18
17:22

Aimmune jumps 15% to $25 after DBV withdraws Viaskin Peanut application

AIMT

Aimmune

$21.74

-0.15 (-0.69%)

DBVT

DBV Technologies

$14.12

-0.58 (-3.95%)

AIMT Aimmune
$21.74

-0.15 (-0.69%)

12/13/18
PIPR
12/13/18
NO CHANGE
Target $60
PIPR
Overweight
Piper remains buyer of Aimmune into 'catalyst-rich' 2019
Piper Jaffray analyst Christopher Raymond says "strong support" from allergists at Aimmune Therapeutics' "positive" investor day. The analyst continues to like the stock setup and says he remains a buyer of the stock into a "catalyst-rich" 2019. Raymond keeps an Overweight rating on Aimmune with a $60 price target.
12/13/18
GSCO
12/13/18
INITIATION
Target $32
GSCO
Neutral
Aimmune initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Paul Choi initiated coverage of Aimmune Therapeutics with a Neutral rating and $32 price target. The analyst thinks the company's peanut allergy treatment AR101 is more than likely to be approved, but he expects a "relatively slow launch."
12/13/18
CANT
12/13/18
NO CHANGE
Target $64
CANT
Overweight
Aimmune current range an attractive entry point, says Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan sees the current Aimmune Therapeutics trading range as an attractive entry point. He reiterates an Overweight rating on the shares with a $64 price target after attending the company's analyst day.
12/19/18
PIPR
12/19/18
NO CHANGE
PIPR
Overweight
Aimmune retains competitive edge over DBV Technologies, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond thinks the recent disclosure that DBV Technologies' (DBVT) Viaskin Peanut may be excluded from the PDUFA program would likely mean an extended FDA review time, which he said "bodes well" for competitor Aimmune (AIMT), which this morning announced the initiation of its Phase 3 POSEIDON trial assessing the efficacy of AR101 in peanut-allergic children. Given that he reads the trial start as a sign that the FDA remains comfortable with the safety profile of AR101, and his view on AR101's clinical profile, Raymond said he believes Aimmune "retains the competitive edge" over DBV. He keeps an Overweight rating on Aimmune shares.
DBVT DBV Technologies
$14.12

-0.58 (-3.95%)

04/18/18
04/18/18
NO CHANGE
Target $37

Buy
Pediatric allergist sees both DBV, Aimmune winning approval, says Jefferies
Jefferies analyst Eun Yang hosted a discussion panel with a pediatric allergist who believes both both DBV Technologies' (DBVT) Viaskin Peanut and Aimmune's (AIMT) AR101 will be approved by the FDA. The allergist thinks Viaskin would be preferable due to its lower burden of monitoring and AR101 would be preferred due to its stronger efficacy, Yang tells investors in a research note. The doctor believes choice of treatment, if both are approved, will depend on a patients' goal of treatment and preference. Yang has a Buy rating on DBV Technologies with a $37 price target.
08/20/18
JMPS
08/20/18
NO CHANGE
Target $30
JMPS
Outperform
DBV Viaskin Peanut BLA acceptance could be derisking event, says JMP Securities
After hosting meetings with Kevin Trapp, DBV Technologies' newly appointed Chief Commercial Officer, JMP Securities analyst Liisa Bayko noted the company is prepared to submit its BLA for Viaskin Peanut in October and she looks for acceptance 60 days later, which she said would be the first positive milestone for the company and could be a "meaningful derisking event." Viaskin Peanut is eligible for priority review and her expectation is that DBV will receive it, added Bayko, who reiterated her Outperform rating and $30 price target on the shares.
09/13/18
STFL
09/13/18
INITIATION
Target $35
STFL
Buy
DBV Technologies initiated with a Buy at Stifel
Stifel analyst Derek Archila initiated DBV Technologies with a Buy rating and a price target of $35, saying the stock offers a "favorable" risk-reward over the next 12 months. Archila acknowledges investors' skepticism due to the Viaskin peanut missing its Phase 3 lower confidence level, but adds that his talks with regulatory experts suggest an over 50% probability that the Viaskin Biologic License Application will be accepted and yield an eventual approval.

TODAY'S FREE FLY STORIES

MUX

McEwen Mining

$1.50

0.015 (1.01%)

06:12
10/17/19
10/17
06:12
10/17/19
06:12
Hot Stocks
McEwen Mining reports Q3 production 45,930 gold equivalent ounces »

McEwen Mining reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLL

Whiting Petroleum

$6.65

-0.07 (-1.04%)

06:11
10/17/19
10/17
06:11
10/17/19
06:11
Upgrade
Whiting Petroleum rating change  »

Whiting Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 06

    Nov

IGLD

Internet Gold

$18.90

(0.00%)

06:08
10/17/19
10/17
06:08
10/17/19
06:08
Hot Stocks
Internet Gold sees Searchlight Transaction closing on November 7 »

Internet Gold announced,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STI

SunTrust

$68.28

0.23 (0.34%)

06:07
10/17/19
10/17
06:07
10/17/19
06:07
Earnings
SunTrust reports Q3 EPS $1.34, consensus $1.41 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 12

    Nov

ERIC

Ericsson

$8.63

0.175 (2.07%)

06:07
10/17/19
10/17
06:07
10/17/19
06:07
Conference/Events
Ericsson to host investor update conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

UNTY

Unity Bancorp

$21.12

-0.45 (-2.09%)

06:06
10/17/19
10/17
06:06
10/17/19
06:06
Earnings
Breaking Earnings news story on Unity Bancorp »

Unity Bancorp reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$9.06

-0.02 (-0.22%)

, AMZN

Amazon.com

$1,777.43

8.73 (0.49%)

06:06
10/17/19
10/17
06:06
10/17/19
06:06
Hot Stocks
Ford introduces North America's largest electric vehicle charging network »

Ford (F) is offering its…

F

Ford

$9.06

-0.02 (-0.22%)

AMZN

Amazon.com

$1,777.43

8.73 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 21

    Nov

CREE

Cree

$47.37

-1.38 (-2.83%)

06:06
10/17/19
10/17
06:06
10/17/19
06:06
Recommendations
Cree analyst commentary  »

Cree guidance to miss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 30

    Oct

WNS

WNS Holdings

$60.62

0.85 (1.42%)

06:04
10/17/19
10/17
06:04
10/17/19
06:04
Earnings
WNS Holdings sees FY20 adjusted EPS $2.93-$3.08, consensus $2.88 »

Sees FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 11

    Nov

WNS

WNS Holdings

$60.62

0.85 (1.42%)

06:03
10/17/19
10/17
06:03
10/17/19
06:03
Earnings
WNS Holdings reports Q2 adjusted EPS 79c, consensus 67c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 11

    Nov

CMA

Comerica

$65.50

-1.505 (-2.25%)

06:02
10/17/19
10/17
06:02
10/17/19
06:02
Downgrade
Comerica rating change  »

Comerica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNB

F.N.B.

$12.02

0.09 (0.75%)

06:01
10/17/19
10/17
06:01
10/17/19
06:01
Earnings
F.N.B. reports Q3 EPS 31c, consensus 29c »

Reports Q3 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 13

    Nov

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$298.46

-0.44 (-0.15%)

05:58
10/17/19
10/17
05:58
10/17/19
05:58
General news
Boris Johnson announces 'great new' Brexit deal »

Prime Minister of the…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$298.46

-0.44 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$298.46

-0.44 (-0.15%)

05:55
10/17/19
10/17
05:55
10/17/19
05:55
General news
European Commission President says Brexit deal has been reached »

President of the European…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$298.46

-0.44 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEGRY

Weir Group

$0.00

(0.00%)

05:51
10/17/19
10/17
05:51
10/17/19
05:51
Downgrade
Weir Group rating change  »

Weir Group downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPHHF

Sophos Group

$0.00

(0.00%)

05:50
10/17/19
10/17
05:50
10/17/19
05:50
Downgrade
Sophos Group rating change  »

Sophos Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASOMY

Asos

$0.00

(0.00%)

05:49
10/17/19
10/17
05:49
10/17/19
05:49
Upgrade
Asos rating change  »

Asos upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

BC

Brunswick

$55.47

0.46 (0.84%)

05:48
10/17/19
10/17
05:48
10/17/19
05:48
Downgrade
Brunswick rating change  »

Brunswick downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

BBT

BB&T

$53.00

0.25 (0.47%)

05:47
10/17/19
10/17
05:47
10/17/19
05:47
Earnings
BB&T reports Q3 adj. EPS $1.07, consensus $1.03 »

Reports Q3 revenue $3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 08

    Nov

ASML

ASML

$254.52

-13.04 (-4.87%)

05:45
10/17/19
10/17
05:45
10/17/19
05:45
Downgrade
ASML rating change  »

ASML downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

PFBC

Preferred Bank

05:43
10/17/19
10/17
05:43
10/17/19
05:43
Downgrade
Preferred Bank rating change  »

Preferred Bank downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

SAM

Boston Beer

$382.92

-4.92 (-1.27%)

05:41
10/17/19
10/17
05:41
10/17/19
05:41
Upgrade
Boston Beer rating change  »

Boston Beer upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

SBNY

Signature Bank

$118.68

-0.1 (-0.08%)

05:41
10/17/19
10/17
05:41
10/17/19
05:41
Earnings
Signature Bank reports Q3 EPS $2.75, consensus $2.70 »

Reports Q3 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 29

    Oct

NGG

National Grid

$57.08

0.305 (0.54%)

05:34
10/17/19
10/17
05:34
10/17/19
05:34
Upgrade
National Grid rating change  »

National Grid upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGVSF

Tryg

$0.00

(0.00%)

05:33
10/17/19
10/17
05:33
10/17/19
05:33
Upgrade
Tryg rating change  »

Tryg upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.